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ABSTRACT
Background. Half of the patients with colorectal cancer
develop liver metastases during the course of their disease.
The aim of the present study was to assess the efﬁcacy of
radioimmunotherapy (RIT) with a radiolabeled monoclonal
antibody (mAb) to treat experimental colorectal liver
metastases.
Methods. Male Wag/Rij rats underwent a minilaparotomy
with intraportal injection of 1 9 10
6 CC531 tumor cells.
The biodistribution of
111In-labeled MG1, 1 day after
intravenous administration, was determined in vivo and
compared with that of an isotype-matched control antibody
(UPC-10). The maximal tolerated dose (MTD) of
177Lu-
labeled MG1 was determined and the therapeutic efﬁcacy
of
177Lu-MG1 at MTD was compared with that of
177Lu-
UPC-10 and saline only. RIT was administered either at the
day of tumor inoculation or 14 days after tumor inocula-
tion. Primary endpoint was survival.
Results.
111In-MG1 preferentially accumulated in CC531
liver tumors (9.2 ± 3.7%ID/g), whereas
111In-UPC-10 did
not (0.8 ± 0.1%ID/g). The MTD of
177Lu-MG1 was
400 MBq/kg body weight. Both the administration of
177Lu-MG1 and
177Lu-UPC-10 had no side-effects except a
transient decrease in body weight. The survival curves of
the group that received
177Lu-UPC-10 and the group that
received saline only did not differ (P = 0.407). Adminis-
tration of
177Lu-MG1 RIT immediately after surgery
improved survival signiﬁcantly compared with
administration of
177Lu-UPC-10 (P = 0.009) whereas
delayed treatment did not (P = 0.940).
Conclusion. This study provides proof of principle that
RIT can be an effective treatment modality for microscopic
liver metastases, whereas RIT is not effective in larger
tumors.
Colorectal cancer (CRC) is the third most common
cancer affecting both men and women in the Western
world.
1,2 CRC has a worldwide 5-year survival of 40–60%
and prognosis is mainly determined by the presence of
local or distant metastases.
3 The liver mostly is the ﬁrst site
of haematogenous dissemination of CRC. Twenty-ﬁve
percent of the patients have liver metastases at the time of
presentation and another 25% of the patients with CRC
develop liver metastases within 2 years after surgical
resection.
4,5 Development of these metachronous liver
metastases is hypothesized to be the result of circulating
tumor cells or activation of dormant microscopic tumors in
the liver. A second hypothesis is that small liver tumors
remain undetected at the time of diagnosis due to the
limited sensitivity of imaging techniques.
6 For these rea-
sons, patients with stage III colon cancer or high-risk
patients with stage II colon cancer will receive adjuvant
treatment with 5-ﬂuorouracil (5-FU)-based chemotherapy.
7
However, pyrimidine-antagonists, such as 5-FU, induce
inherent adverse events and the beneﬁcial effect of adju-
vant chemotherapy for stage II patients is still subject of
debate.
8
Radioimmunotherapy (RIT) using radiolabeled mono-
clonal antibodies directed against tumor-associated
antigens offers the opportunity to selectively irradiate
tumor cells, while sparing normal tissues. Several pre-
clinical studies have indicated that RIT can be very
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9–12
Tumor targeting with radiolabeled monoclonal antibodies
has been shown to be particularly efﬁcient in small-volume
disease and minimal residual disease.
11,13 The aim of the
present study was to test the hypothesis that RIT might be
an effective treatment modality to treat microscopic and
small liver tumors.
MATERIALS AND METHODS
The in vivo experiments were performed in rats using a
MG1 monoclonal antibody (mAb) directed against a syn-
geneic colon carcinoma cell line (CC531). Sequential
experiments were performed to optimize and demonstrate
the feasibility of RIT in this animal model. First, the
internalization kinetics of the MG1 binding to its antigen
were determined. Secondly, the maximum tolerated dose
(MTD) of
177Lu-MG1 was determined. Next, the biodis-
tribution of
111In-labeled MG1 was examined in Wag/Rij
rats with CC531 liver tumors and compared with the bio-
distribution of an isotype-matched irrelevant control
antibody (UPC-10). Subsequently, the therapeutic efﬁcacy
of RIT using
177Lu-labeled MG1 to treat liver metastases
was tested in two disease stages.
Cell Line and Monoclonal Antibody
The syngeneic rat colonic carcinoma cell line CC531 is
derived from colonic tumors of Wag/Rij rats exposed to
1,2-dimethylhydrazine.
14 CC531 was cultured and sus-
pended as described previously.
15 MG1 mAb was
purchased from Antibodies for Research Applications BV
(Gouda, The Netherlands). The MG1 mAb is a murine
IgG2a antibody, raised by immunization of mice with
CC531 colon carcinoma cells. It recognizes a cell surface
antigen of about 80 kDa, localizes preferentially in the
CC531 tumors when injected in rats, and has minimal
cross-reactivity with other cell types.
16,17 MG1 has a high
afﬁnity (Kd = 1.0 nM) for the antigen expressed on CC531
tumor cells.
18 UPC-10 is also a murine IgG2a antibody and
is directed against b-2-6-linked fructosan (Sigma Life
Science, Zwijndrecht, The Netherlands).
Radiolabeling
177Lu is a beta-emitting radionuclide with a maximum
beta-energy of 0.497 MeV and a half-life of 6.7 days that
is commonly used in radioimmunotherapy.
111In has highly
similar physical characteristics to
177Lu but does not emit
beta-particles and was therefore used as surrogate radio-
nuclide for
177Lu in in vitro and biodistribution
experiments.
111In was purchased from Covidien BV
(Petten, The Netherlands) and
177Lu from IDB Holland BV
(Baarle Nassau, The Netherlands).
111In- and
177Lu-label-
ing of the MG1-DTPA antibody conjugate was performed
and radiochemical purity and immunoreactivity were
conﬁrmed as described previously.
15 Speciﬁc activity of
the
111In-MG1 and
111In-UPC-10 preparations was
218 kBq/lg and 200 kBq/lg, respectively. Speciﬁc activ-
ity of the
177Lu-UPC-10 preparation was 588 kBq/lg.
Average speciﬁc activity of the
177Lu-MG1 preparations
was 494 kBq/lg (range 396–629 kBq/lg). The radio-
chemical purity of all preparations exceeded 90%.
Internalization of MG1
CC531 cells were cultured to conﬂuency in six-well
plates and were incubated with 1.1 kBq
111In-MG1 for 0.5,
1, 2, 4, 6, and 24 h, in 2 ml binding buffer (RPMI 1640,
0.5% BSA), at 37C in a humidiﬁed atmosphere with 5%
CO2. After incubation, 1 ml acid wash buffer (0.1 M HAc,
0.15 M NaCl, pH 2.6) was added for 10 min to remove the
membrane-bound fraction of
111In-MG1. Subsequently, the
cells were harvested from the six-well plates and the
amount of activity was measured in a shielded 3-inch-well-
type gamma counter (Wizard, Pharmacia-LKB, Sweden).
Nonspeciﬁc binding and internalization was determined by
coincubation with an excess of 6.7 nM unlabeled MG1.
Animals
Ten- to 12-week-old male Wag/Rij-rats with mean
weight of 250 g were obtained from Charles River Labo-
ratories (Sulzfeld, Germany). Rats were accustomed to
laboratory conditions for 1 week prior to experimental use
and housed under nonsterile, standard laboratory condi-
tions (temperature 20–24C; relative humidity 50–60%;
12 h light/12 h dark) on sawdust in ﬁlter-topped cages (two
or three rats per cage) with free access to animal chow
(Ssniff Voer, Soest, The Netherlands) and water. All
experiments were conducted in accordance with the prin-
ciples laid out by the revised Dutch Act on Animal
Experimentation (1997) and approved by the institutional
Animal Welfare Committee of the Radboud University
Nijmegen.
Maximum Tolerated Dose
Fifteen healthy male Wag/Rij rats were injected
intravenously with increasing doses of
177Lu–MG1 (400,
600, and 800 MBq/kg, respectively). Five rats were used
as controls, receiving an intravenous injection with the
saline only. Blood samples were collected twice during
the ﬁrst week and weekly for the following 7 weeks post
injection. White blood cell (WBC) counts and platelet
2066 G. M. de Jong et al.counts were analyzed by ADVIA 120 Hematology System
(Siemens Medical Solutions Diagnostics, Deerﬁeld, USA).
Toxicity was evaluated by monitoring the body weight of
the animals, general condition, and blood cell counts.
When the humane endpoint ([20% body weight loss,
physical inactivity or signs of severe toxicity such as
infections, bleeding, or diarrhea) was reached, rats were
killed using O2/CO2 asphyxiation and immediately dis-
sected. After 2 months all remaining rats were killed.
MTD was deﬁned as the highest activity (MBq/kg) at
which 100% of the animals survived without reaching the
humane endpoint.
Tumor Inoculation
The surgical procedures to induce intrahepatic CC531
tumors for the biodistribution and therapy studies were
carried out under clean conditions. Prior to operation, rats
received carprofen subcutaneously (5 mg/kg body weight)
as analgesic. Immediately after the onset of general
anaesthesia (isoﬂurane/O2/N2O), the abdomen was shaved
and disinfected with 70% ethanol. During the operation,
rats were placed on a warm mattress to limit heat loss and
chloramphenicol (20 mg/g) eye drops were administered to
prevent dehydration of the eyes. Rats subsequently under-
went a 3-cm midline minilaparotomy. After the abdomen
was opened, the intestines were gently lifted out of the
abdomen, wrapped in moist gauzes, and placed on the left
side of the animal, exposing the portal vein. Using a 29-
gage needle and 1-ml syringe, 1 9 10
6 CC531 tumor cells,
suspended in 0.1 ml phosphate-buffered saline (PBS), were
injected intraportally. To prevent excessive bleeding, the
portal vein was punctured through mesenteric fat, which
served as a tamponade. In addition, the puncture area was
covered for a few minutes with a cotton stick. The mus-
cular layer of the abdomen was closed by continuous
absorbable braided 3/0 sutures and the skin was closed by
iron wound clips. Ten milliliters of warmed saline was
injected subcutaneously for rehydration. Rat cages were
kept on a warmed mattress for the ﬁrst day. The rats
received daily analgesic subcutaneous injections for
2 days.
Biodistribution
To determine the uptake of
177Lu-MG1 in normal tissues
and liver tumors, the biodistribution of
111In-MG1 was
determined after intravenous injection (n = 4). Likewise,
the biodistribution of
111In-UPC-10 was determined in a
separate group (n = 4). In this experiment, on day 0 eight
Wag/Rij rats underwent the surgical procedure to induce
intrahepatic tumor growth as described above. Twenty days
later, rats received a single intravenous injection with
either 0.4 MBq
111In-MG1 (1.7 lg MG1 mAb per rat) or
0.4 MBq
111In-UPC-10 (1.9 lg UPC-10 mAb per rat), in
0.2 mL PBS, 0.5% bovine serum albumin (BSA). On day
21 the rats were killed using O2/CO2 asphyxiation and
dissected. Uptake in normal tissues and liver tumors was
measured as described previously.
18 The results were
expressed as percentage of the injected dose per gram tis-
sue (%ID/g).
Radioimmunotherapy
The therapeutic efﬁcacy of RIT with
177Lu-MG1 was
determined by the random assignment of 56 rats to receive
an intravenous injection of either
177Lu-MG1,
177Lu-UPC-
10 or saline 2–4 h after intraportal injection of CC531 cells
(n = 14 each). In a separate group,
177Lu-MG1 was also
administered 14 days after tumor cell inoculation (n = 14)
as shown in Fig. 1. Figure 2 shows an example of the
tumor nodules as present in the liver 14 days after inocu-
lation. In all groups, the administered activity was
300 MBq/kg in 0.25 ml PBS in a single dose. The primary
endpoint was survival. Toxicity was evaluated by moni-
toring body weight and general condition. Rats were
monitored daily by two experienced and independent ani-
mal technicians who were blinded to the therapeutic
regime. When the humane endpoint was reached, rats were
euthanized by O2/CO2 asphyxiation and immediately dis-
sected. All remaining rats were euthanized and dissected
120 days after the operation. At dissection, the abdominal
cavity was carefully inspected, with special attention to the
liver parenchyma. All macroscopic tumor deposits in the
liver were resected and weighed. When no macroscopic
tumor deposits were present, the liver was sliced in 0.5-cm-
FIG. 1 Time schedule of the radioimmunotherapy experiment
Radioimmunotherapy and Colorectal Liver Metastases 2067thick slices for routine histopathological hematoxylin and
eosin (H&E) staining. Microscopic tumor growth was
scored as either present or absent.
Statistical Analysis
Statistical analysis was performed using the SPSS soft-
ware (Chicago, IL) and GraphPad Prism version 4.00
(GraphPad Software, San Diego USA) for Windows.
Sample size was determined by a power calculation based
on an estimated effect of RIT in doubling the survival time
of the treated animals. Multiple comparisons of dichoto-
mous values were analyzed using the one-way analysis of
variance (ANOVA)test. Bonferroni correction for multiple
testing was applied. Survival time was analyzed by Kap-
lan–Meier method and differences were tested by Gehan–
Breslow test since no consistent proportional hazard ratio
was to be expected. The level of statistical signiﬁcance was
set at P\0.05. Medians, 75th-, and 25th survival per-
centiles and standard error were used to describe
continuous data.
RESULTS
Internalization of MG1
After 6 h, 13 ± 1% of the incubated
111In-MG1 was
bound to the target cells (Fig. 3). MG1 was internalized
gradually by the target cells: after 6 h, 38% of the cell-
associated
111In-MG1 was internalized.
Maximum Tolerated Dose
Survival of the animals in the MTD study is summarized
in Fig. 4. During the ﬁrst days post injection, all groups
receiving
177Lu-MG1 lost weight. After 18 days, 80% of
the animals that received either 800 MBq/kg or 600 MBq/
kg
177Lu-MG1 had lost more than 20% of their body
weight and were euthanized. These rats all showed signs of
dehydration and poor general condition. There was no
diarrhea. At dissection the thymus could not be detected,
the spleen was small, and the intestines appeared fragile.
Moreover, seven of these rats had signs of infarction and
bleeding in the kidneys, testicles, and around the spleen.
The rats that received 400 MBq/kg lost a maximum of 7%
of their body weight, reaching nadir on day 5, and showed
signs of clinical discomfort such as inactive behavior
during this period. The control animals on average gained
3% of their relative body weight during the corresponding
period. After 5 days the animals that had received
400 MBq/kg started to gain weight again, as the control
animals.
WBC and platelet counts are shown in Fig. 5a, b. All
groups showed a similar decrease in WBC during the ﬁrst
14 days post injection, with minimum levels of less than
1% of the initial value. In all remaining rats, WBC started
to recover from day 20, reaching a normal WBC count
FIG. 2 Anterior site of liver with metastases 14 days after intraportal
injection of 1 9 10
6 CC531 tumor cells
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FIG. 3 Internalization of MG1 in the CC531 tumor cell. The
percentage activity of
111In-MG1 present in the cell bound fraction
(blue line) and in the internalized fraction (yellow line) is depicted as
mean ± standard error on the mean (SEM). In addition, nonspeciﬁc
binding (green line) and internalization (orange line) are given
2068 G. M. de Jong et al.after 2 months. Platelets started to decline 4 days after
injection and started to recover after 2 weeks.
Biodistribution of
111In-Labeled MG1
The biodistribution of
111In-MG1 and
111In-UPC-10 in
rats with intrahepatic CC531 tumors is summarized in
Fig. 6. There was high and speciﬁc uptake of
111In-MG1 in
the tumor of 9.2 ± 3.7%ID/g, as compared with the tumor
uptake of
111In-UPC-10 (0.8 ± 0.1%ID/g) 1 day post
injection. Uptake of MG1 in other organs did not exceed
1.2%ID/g. The tumor-to-blood ratio of
111In-MG1 was
7.1 ± 1.3 compared with 0.3 ± 0.01 for
111In-UPC-10.
Efﬁcacy of Radioimmunotherapy Using
177Lu-MG1
The relative body weight of the rats during the ﬁrst
30 days of the study, expressed as the percentage of the
body weight on the day of surgery, is depicted in Fig. 7.
Compared with administration of the saline only, admin-
istration of both
177Lu-MG1 and
177Lu-UPC-10 reduced
body weight, indicating a nonspeciﬁc radiation effect. On
either time point, 5 days after injection of the radiophar-
maceutical, the relative body weight decreased about 4%.
However, no other signs of clinical discomfort were
observed during the initial posttreatment period, and
bodyweight recovered quickly in the course of the study. In
addition, no signs of wound healing disorders were
observed.
One rat of the group treated with
177Lu-MG1 on day 14
was euthanized without completely fulﬁlling the humane
endpoint criteria and was therefore excluded from the
survival analysis. Altogether 50 rats reached the humane
endpoint in the course of the experiment and were killed.
All of these rats, including all rats in the control group, had
developed liver tumors at that moment. The mean tumor
weight of the group treated with
177Lu-MG1 on day 14 was
100
60
20
80
40
06 0
Days
20 10 50 40 30
Survival
(Percent)
400 MBq/kg
600 MBq/kg
800 MBq/kg
FIG. 4 Survival curves of the animals in the MTD study. Lines
represent groups receiving escalating doses of
177Lu-MG1; 400 MBq/
kg (blue line), 600 MBq/kg (yellow line), and 800 MBq/kg (green
line). Note that the control group is not represented in the analyses,
since all rats survived the experimental period
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FIG. 5 Hematological toxicity of
177Lu-MG1. Both WBC (a) and
platelet counts (b) are given. Lines represent groups receiving
escalating activities of
177Lu-MG1; 400 MBq/kg (yellow line),
600 MBq/kg (green line), and 800 MBq/kg (orange line) and the
control group (blue line). Symbols represent mean values with
standard error. No dose-response pattern was seen in these groups
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weight of each of the other groups (P\0.05 for each
comparison). Twenty-seven rats also had tumor nodules
elsewhere in the abdomen, including at the initial puncture
site. One rat of the group treated with
177Lu-MG1 on day 0
developed jaundice 90 days after start of the experiment
and was found to have an obstructing tumor at the liver
hilus. One hundred and twenty days after tumor cell
inoculation ﬁve rats (three in the group that was treated
with
177Lu-MG1 on day 0 and one each in the groups
treated with
177Lu-UPC-10
177 on day 0 or
177Lu-MG1 on
day 14) were still alive, without clinical signs of liver
tumors. At dissection none of the rats had macroscopic
tumor growth. Histopathological examination of the livers
showed no microscopic tumor nodules either.
The survival curves are shown in Fig. 8. Statistical
analysis showed that the survival curves of the groups
receiving
177Lu-UPC-10 or the saline only did not differ
(P = 0.518). Therefore, in further analysis, the results were
compared with the group receiving
177Lu-UPC-10. First,
Kaplan–Meier survival analysis was performed, which
showed that overall survival curves of the groups treated
14
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FIG. 6 Biodistribution. The uptake of
111In-DTPA-MG1 (blue line) and
111In-
DTPA-UPC-10 (yellow line) on day 20
is depicted as mean ± SEM
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FIG. 7 Course of body weight. The mean (±SEM) relative body
weight, with respect to preoperative weight, is given for the MG1 D0
group (yellow line), MG1 D14 group (green line), UPC-10 group
(orange line), and the control group (blue line)
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FIG. 8 Survival curves of the animals in the therapy study. Lines
represent groups receiving 300 MBq/kg
177Lu-MG1 on D0 (yellow
line), 300 MBq/kg
177Lu-MG1 on D14 (green line), 300 MBq/kg
177Lu -UPC-10 group (orange lne) or saline (blue line)
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177Lu-MG1 and
177Lu-UPC-10 were signiﬁcantly
different (P = 0.029). Administration of RIT immediately
after surgery improved survival signiﬁcantly compared
with administration of the control antibody (P = 0.009)
and compared with delayed treatment (P = 0.027).
Administration of RIT 14 days after tumor inoculation did
not improve survival compared with administration of the
control antibody (P = 0.940). The median survival of the
animals treated with
177Lu-UPC-10 was 46 ± 6 days. The
75th and 25th survival percentiles of this group were
34 ± 9 days and 49 ± 3 days, respectively. The median
survival of the rats treated with
177Lu-MG1 on the day of
surgery was 55 ± 24 days and the 75
th and 25
th survival
percentile of this group improved to 50 ± 7 days and
97 ± 1 days, respectively.
DISCUSSION
The results of the present study show that RIT can
increase survival in rats with microscopic tumors of colo-
rectal origin in the liver. A well-characterized rat model
was used in the study. The syngeneic rat colon carcinoma
cell line CC531 exhibits a reproducible growth pattern in
Wag/Rij rats.
19 We already demonstrated that MG1 has a
high afﬁnity for its antigen on the CC531 cell membrane.
18
In addition, the present data demonstrate that MG1 is
gradually internalized by CC531 cells, which is a favorable
characteristic for RIT since it increases tumor retention of
the radiolabel and consequently enhances the radiation
dose absorbed by the tumor. The remarkable decrease in
cell surface binding of the labeled antibody between 6 and
24 h might indicate either release of the radiolabeled mAb
from the cell surface or shedding of the antibody–antigen
complex after internalization. Both intrasplenic and intra-
portal injection of (syngeneic) tumor cells in rodents may
result in liver metastases with a high reproducibility.
20 In
the present model, tumor growth in the liver occurs in
100% of the untreated animals, with no mortality or weight
loss due to the surgical procedure. The in vivo tumor tar-
geting potential of MG1 mAb for CC531 liver tumor is
demonstrated by its speciﬁc accumulation in CC531 liver
tumors and is in concordance with ﬁndings in previous
animal studies on peritoneal carcinomatosis.
15,16,19 In
addition, the MTD of
177Lu-MG1 for healthy male Wag/rij
rats was found to be approximately 400 MBq/kg with dose-
limiting hematological toxicity.
Currently, adjuvant treatment strategies after surgery
focus on the rate of dissemination at the time of diagnosis.
For patients with stage III CRC, adjuvant 5-FU-based
chemotherapy after resection of the primary tumor is most
often recommended to improve disease-free survival.
7
However, pyrimidine antagonists, such as 5-FU, have
inherent adverse events. Adjuvant systematic or regional
therapies after surgery are also hypothesized to decrease
relapse rates in patients with stage II colon cancer. How-
ever, a recent systematic review by Figueredo et al. showed
that adjuvant systemic 5-FU-based chemotherapy has only
small beneﬁt for patients with stage II CRC and should
therefore only be considered in a carefully selected group.
Regional adjuvant chemotherapy (by portal vein infusion)
has shown similar results, but is mostly abandoned because
of the technical difﬁculties of the procedure. As for speciﬁc
immunotherapy, the authors report enhanced recurrence-
free survival, but data on overall survival are lacking due to
the short follow-up period. Moreover, some of these
treatments (for example, active speciﬁc immunotherapy
with autologous tumor cell vaccines) are complicated
procedures, requiring a dedicated laboratory to obtain an
active vaccine and a responsive host. Finally, reports on
other adjuvant treatments have been limited and did not
show signiﬁcant beneﬁcial effects.
8 RIT with radiolabeled
monoclonal antibodies directed against tumor-associated
antigens has evolved from an appealing concept to one of
the standard treatment options for patients with non-
Hodgkin’s lymphoma.
21,22 RIT offers the opportunity to
selectively irradiate tumor cells, while sparing normal tis-
sues. Another advantage of RIT is the crossﬁre effect,
which means that nontargeted cells are irradiated due to
radiolabeled antibody uptake by surrounding cells. Because
of the relative radiosensitivity of colorectal carcinoma and
the availability of mAbs against CRC-associated antigens,
the efﬁcacy of RIT using radiolabeled mAbs against CRC
has been investigated in various preclinical clinical studies.
For example, Behr et al. demonstrated that, in a nude-
mouse model for lung metastases of CRC, RIT (
131I-anti-
CEA antibody) cured half of the animals whereas equitoxic
chemotherapy only prolonged life for a few weeks.
23 Aarts
et al. demonstrated that adjuvant RIT (
177Lu-MG1 mAb)
after debulking of peritoneal carcinomatosis in a rat model
improved survival, whereas adjuvant heated intraperitoneal
chemotherapy did not and was considered more toxic.
12 To
date, only a limited number of clinical trials have studied
the effect of RIT in CRC patients. A review of this small
number of phase I/II RIT trials in patients with gross
metastatic disease precludes any ﬁrm conclusion on the
potential of RIT in the treatment of CRC.
24 Most phase I/II
clinical RIT studies were carried out in pretreated patients
with bulky disease, while it has been shown that RIT may
be more effective in patients with small-volume disease. So
far, only one study investigated the efﬁcacy of adjuvant
RIT in patients with minimal disseminated disease.
25 In
this phase II study 21 patients with small-volume meta-
static disease (B3 cm), all either chemorefractory or
chemointolerant, were included. Fourteen patients had liver
metastases; remaining patients had either lung metastases
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injection of
131I-MN14 IgG at 2.2 GBq/m
2 (MTD) and
follow-up was as long as 36 months. The therapeutic
infusion was tolerated well by all patients, with mild
nausea as the only acute side-effect and only mild leuco-
and thrombocytopenia. Response was measured in 11 out
of 21 patients (52%), which is similar to response rates
achieved with 5-FU/leucovorin-based chemotherapeutic
regimens.
Our results support the suggestion that RIT could be
efﬁcacious in CRC patients with small liver tumors that
cannot be diagnosed at the time of surgery of the primary
tumor and constitute an enhanced risk of disease recurrence.
The survival analysis of this study shows that immediate
administration of adjuvant RIT will mainly result in an
improvement of late survival. The data suggest that RIT
delays tumor growth in early stages of metastatic develop-
ment, but does not seem to affect the number of cures and is
not effective in animals with larger liver tumors, as dem-
onstrated in the group receiving RIT 14 days after tumor
inoculation. For asyet unknown reasons the tumorweight in
this group was found to be higher than in the other groups.
One rat that was treated with the radiolabeled irrelevant
antibody (UPC-10) did not develop any liver tumors. Most
likely, this rat did not receive the proper tumor cell inocu-
lation at the start of the experiment. The marked difference
in survival between early and late administration of RIT
could very well be the result of the inverse correlation
between uptake and consequent therapeutic efﬁcacy of
radiolabeled antibodies and tumor size.
26,27 The growth of
minimal disease into larger tumors has shown to have a
negative effect on the therapeutic efﬁcacy of radiolabeled
mAbs.
28 These conclusions are supported by the outcome of
clinical studies demonstrating that tumor targeting with
radiolabeled monoclonal antibodies is particularly efﬁcient
in small-volume disease and minimal residual disease.
23,25
Moreover, the current study shows that RIT can be admin-
istered intravenously in a single dose and does not show
major side-effects such as infections or impaired wound
healing. The latter is in line with the ﬁndings of Aarts et al.,
who observed that RIT did not impair wound healing.
29
If application of RIT is considered in a clinical setting,
where surgery-related complications could require inten-
sive care for the patient, special care should be taken to
ensure minimal exposure of medical personnel to radiation.
The most promising radionuclides for adjuvant RIT in
CRC are beta-emitting isotopes such as
131I,
90Y, and
177Lu.
30 An important advantage of using
177Lu for RIT (as
compared with
131I) in a clinical setting is the low abun-
dance of gamma radiation (11%, 208 keV), lowering the
radiation burden to the environment and allowing diag-
nostic imaging after a therapeutic dose RIT has been
administered to a patient.
CONCLUSION
This study provides proof of principle that RIT using
177Lu-labeled MG1 mAb at MTD increases survival in rats
with microscopic liver metastases and encourages the
implementation of clinical trials studying the effect of RIT
in CRC patients undergoing surgery and at high risk for
disease recurrence. Further preclinical studies will be per-
formed in this well-deﬁned animal model to optimize the
use of (adjuvant) RIT in the treatment of CRC and to
compare these effects with the treatment of CRC with
adjuvant chemotherapy.
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